Loading...
 

ARCHIVE

Pneumon 2019, 32(4):155-160
Ambroxol … more than an expectorant The benefit of using ambroxol in chronic respiratory diseases?
Authors Information
1Sanofi Greece, Kallithea, Athens, Greece
2Intensive Care Unit, 1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece
3Oncology unit, 3rd Department of Internal Medicine, University of Athens, Sotiria Hospital, Athens, Greece
42nd Respiratory Medicine Department, Attikon Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
51st Respiratory Medicine Department, Sotiria Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
Abstract
Chronic respiratory diseases comprise of chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases and bronchiectasis, amongst others. Most of these long-term diseases are not curable and cause an enormous economic burden. Mucoregulators such as ambroxol have been used for decades as a treatment for pulmonary diseases, in order to reduce the burden of the disease and improve quality of life by promoting mucus clearance. Effects of ambroxol include the increase of surfactant production, cytokine reduction and counteracting of oxidative stress in the lungs. Positive effects of ambroxol have been described in vitro and in clinical studies for COPD, chronic bronchitis as well as in acute respiratory infections. In addition, antiviral, antibacterial and antifungal properties have been demonstrated. Αmbroxol has a good safety profile. In this short review article, the current clinical knowledge on Ambroxol is summarized.